6286-85-7Relevant articles and documents
2′-Thiophenecarboxaldehyde derived thiosemicarbazone metal complexes of copper(II), palladium(II) and zinc(II) ions: Synthesis, spectroscopic characterization, anticancer activity and DNA binding studies
Haribabu, J.,Jagadeesh, M.,Jang, Joonkyung,Karvembu, R.,Kumar Chitumalla, Ramesh,Lavanya, M.,Ramaiah, K.,Suresh Yadav, C.,Varada Reddy, A.
, (2021)
Heterocyclic 5′-methyl-2-thiophenecarboxaldehyde-N(4)-un/substituted thiosemicarbazones (1–3) and their metal complexes with copper(II), palladium(II) and zinc(II) ions (4–11) were synthesized and characterized by using different spectroscopic techniques like FT-IR, 1H, 13C NMR, UV–Visible and electron paramagnetic spectroscopy, etc. The crystal structures of the synthesized thiophene thiosemicarbazone ligands 1, 2 and 3 were determined unambiguously by single-crystal X-ray diffraction analysis. The EPR spectra of the copper(II) complexes, 4, 6 and 9 have shown rhombic, normal axial and inverse axial symmetry respectively. Furthermore, the DNA binding study was performed on calf-thymus DNA by absorbance, fluorescence and viscosity measurement methods. Notably, the copper(II) and palladium(II) complexes have strong DNA binding interactions compared to the zinc(II) complexes. The DNA binding constants measured for these complexes were found to be in the range of 1.83 × 104–1.45 × 105 M?1. Further, the newly synthesized complexes were also tested for their in vitro anticancer activity against three types of human cancer cell lines (COLO-205, MCF-7 and HepG-2) and one normal cell line (HEK-293). Importantly, the zinc(II) complex (8) exhibited potent anticancer activity against HepG-2 with an IC50 value of 11.65 ± 1.753 μM compared to the standard drug cis-platin. The copper(II) complex, 9 against COLO- 205 with an IC50 value of 23.08 ± 1.354 μM, complex 4 against MCF-7 and HepG-2 with IC50 values of 39.35 ± 1.825 μM and 35.26 ± 0.354 μM, respectively, and complex 6 against HepG-2 with an IC50 value of 38.30 ± 1.385 μM have displayed moderate activity compared to the reference drug cis-platin.
New hydrazinothiazole derivatives of usnic acid as potent TDP1 inhibitors
Filimonov, Aleksander S.,Chepanova, Arina A.,Luzina, Olga A.,Zakharenko, Alexandra L.,Zakharova, Olga D.,Ilina, Ekaterina S.,Dyrkheeva, Nadezhda S.,Kuprushkin, Maxim S.,Kolotaev, Anton V.,Khachatryan, Derenik S.,Patel, Jinal,Leung, Ivanhoe K.H.,Chand, Raina,Ayine-Tora, Daniel M.,Reynisson, Johannes,Volcho, Konstantin P.,Salakhutdinov, Nariman F.,Lavrik, Olga I.
, (2019/10/28)
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a promising therapeutic target in cancer therapy. Combination chemotherapy using Tdp1 inhibitors as a component can potentially improve therapeutic response to many chemotherapeutic regimes. A new set of usnic acid derivatives with hydrazonothiazole pharmacophore moieties were synthesized and evaluated as Tdp1 inhibitors. Most of these compounds were found to be potent inhibitors with IC50 values in the low nanomolar range. The activity of the compounds was verified by binding experiments and supported by molecular modeling. The ability of the most effective inhibitors, used at non-toxic concentrations, to sensitize tumors to the anticancer drug topotecan was also demonstrated. The order of administration of the inhibitor and topotecan on their synergistic effect was studied, suggesting that prior or simultaneous introduction of the inhibitor with topotecan is the most effective.
